Gillian McGovern

18 hours ago | pharmacytimes.com | Gillian McGovern

The FDA approved penpulimab-kcqz (formerly AK105; Akeso Biopharma Co., Ltd.) for different indications within nonkeratinizing nasopharyngeal carcinoma (NPC).

22 hours ago | pharmacytimes.com | Gillian McGovern

Hormonal contraceptive (HC) initiation in first-time mothers was associated with an increased risk of depression postpartum, wrote authors of a study published in JAMA Network Open. Interestingly, these associations were observed for combined oral contraceptives (COCs), combined nonoral contraceptives (CNOCs), and progestogen-only nonoral contraceptives (PNOCs), but were inconclusive for progestogen-only pills (POPs).1Approximately 248 million women worldwide are estimated by the WHO to use HC.

23 hours ago | pharmacytimes.com | Gillian McGovern

In a randomized, double-blind, placebo-controlled, multicenter, 52-week phase 3 clinical trial (NCT05115942), 270 mg of hydronidone (Gyre Therapeutics) per day is expected to have positive benefits when used for the treatment of liver fibrosis related to chronic hepatitis B (CHB), according to study investigators.1,2 This theory is supported by prior phase 2 clinical trial evidence in which hydronidone with entecavir (Baraclude; Bristol-Myers Squibb) resulted in significant reversal of liver...

23 hours ago | pharmacytimes.com | Gillian McGovern

Investigators of a study published in Science Translational Medicine discovered a critical factor that determines how much scarring will occur following kidney injury in patients with chronic kidney disease (CKD).

2 days ago | pharmacytimes.com | Gillian McGovern

Low-risk β-lactam antibiotic allergy labels (AALs) were successfully evaluated and delabeled by anesthesiologists in the preoperative clinic through a smartphone application, as demonstrated by clinical data published in JAMA Surgery.